| Bioactivity | Berotralstat dihydrochloride is a low toxicity, effective, highly specific, second-generation, synthetic and orally active plasma kallikrein inhibitor used for the research of hereditary angioedema (HAE) attacks. Berotralstat dihydrochloride works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE[1][2]. |
| Name | Berotralstat dihydrochloride |
| CAS | 1809010-52-3 |
| Formula | C30H28Cl2F4N6O |
| Molar Mass | 635.48 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, stored under nitrogen, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture) |
| Reference | [1]. Zuraw B, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial [published online ahead of print, 2020 Oct 21]. J Allergy Clin Immunol. 2020;S0091-6749(20)31484-6. [2]. Manning ME, et al. Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies. Allergy Asthma Proc. 2021;42(4):274-282. |
Berotralstat dihydrochloride
CAS: 1809010-52-3 F: C30H28Cl2F4N6O W: 635.48
Berotralstat dihydrochloride is a low toxicity, effective, highly specific, second-generation, synthetic and orally acti
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.